The Iowa Hawkeyes are fighting recruitment battles on multiple fronts in January. Kirk Ferentz and Co. have fired all cylinders, trying to bolster both the 2026 and the 2027 classes. After securing ...
In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Avidity Biosciences (RNA – Research Report), with a price target of $67.00. The company’s shares closed last Friday at ...
Fintel reports that on December 8, 2025, RBC Capital maintained coverage of Neurocrine Biosciences (NasdaqGS:NBIX) with a Outperform recommendation. As of December 6, 2025, the average one-year price ...
The live webcast for each presentation can be accessed in the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events ...
RBC Capital analyst Gregory Renza maintained a Hold rating on Spruce Biosciences (SPRB – Research Report) yesterday and set a price target of $0.50. Discover outperforming stocks and invest smarter ...
Fintel reports that on April 14, 2025, RBC Capital upgraded their outlook for Neurocrine Biosciences (LSE:0K6R) from Sector Perform to Outperform. As of April 2, 2025, the average one-year price ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy right now. On September 5, RBC Capital raised the firm’s price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to ...
Kathleen P. Gallagher, Chief Program Officer at Avidity Biosciences Inc . (NASDAQ:RNA), a $4.1 billion market cap company whose stock has surged 186% over the past year, recently executed a series of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback